Acasti Pharma, Inc. (ACST) Q3 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, ladies and gentlemen, and welcome to the Acosti Pharma third quarter fiscal 2022 business update conference call. At this time, all participants have been placed on a listen-only mode, and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, David Waldman with Investor Relations. Sir, the floor is yours. Thank you, Holly, and good afternoon, everyone. I'd like to welcome you to Acosti Pharma's fiscal 2022 third quarter conference call. On the call with us this afternoon are Jan D'Alvise, President and CEO, Brian Ford, Chief Financial Officer, Dr. Pierre Lemieux, Chief Operating Officer, Canada, and Chief Scientific Officer, Dr. George Katail, Chief Operating Officer, US, and Prashant Kohli, Vice President of Commercial Operations. Following our prepared remarks, there'll be a Q&A session. Should any questions remain after the call, please contact Crescendo Communications at 212-671-1020. I'd also like to remind everyone that statements on this conference call that are not statements of historical or current fact constitute forward-looking information within the meaning of the Canadian securities laws and forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and the Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of a custody to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, listeners are urged to consider statements labeled with the terms...